Family offices of billionaires target healthcare and biotech startups
The investment arms of high-net-worth individuals, including Stanley Druckenmiller, are directing capital into early-stage healthcare and biotech ventures. Focus areas include gene editing and drug discovery, with activity reported in August.
Sources: msn.com
“This trend underscores how family offices—often more patient than traditional VCs—are filling gaps in deep-tech funding where long-term horizons deter conventional investors.”
Read the original reporting
This is a short summary. The outlets below did the reporting.
This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.